CQ Medical acquires .decimal to boost patient-specific cancer treatment
What's the deal? CQ Medical has acquired .decimal, a move aimed at expanding its patient-specific cancer treatment capabilities. The deal combines CQ Medical's existing oncology portfolio with .decimal's specialised radiation therapy devices and software, which are used to create custom treatment solutions for individual cancer patients.
Financial terms of the acquisition were not disclosed.
Why now? The cancer treatment market is increasingly shifting toward personalised medicine, where therapies are tailored to a patient's specific tumour characteristics rather than relying on one-size-fits-all approaches. Radiation oncology in particular has seen growing demand for patient-specific devices — custom-made tools that shape and direct radiation beams to maximise tumour targeting while minimising damage to healthy tissue.
By acquiring .decimal, CQ Medical positions itself to meet that demand with a broader product offering at a time when hospitals and treatment centres are investing heavily in precision oncology infrastructure.
What could go wrong? Integration is always a risk in acquisitions. Merging two companies' manufacturing processes, sales teams, and product lines can be disruptive — especially in a regulated medical device market where quality standards are non-negotiable. If the transition slows production or delivery timelines, it could frustrate the clinical partners both companies serve.
Competition in the radiation therapy space is also fierce, with larger medtech players investing in their own patient-specific solutions.
The signal: This deal reflects a broader consolidation trend in the medtech sector, where mid-sized companies are snapping up complementary firms to build end-to-end capabilities rather than competing on a single product line. Personalised cancer treatment is no longer a niche — it is becoming the standard of care, and companies that can offer integrated, patient-specific solutions are positioning themselves for long-term growth.
Read more: prnewswire.com
